Update: Autologous Stem Cell Transplantation for Lymphoma and Myeloma
Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.
Date: December 03, 2012
CE Credit Available Until: August 11, 2014
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
Target Audience: Oncology nurses and social workers involved in the treatment of myeloma and lymphoma.
Read: Program Slides | Written Transcript
Listen: Presentation | Q&A Session
Access: Virtual Lecture
Activity Purpose
To educate oncology nurses and social workers about the use of autologous stem cell transplantation (ASCT) in the treatment of myeloma and lymphoma.
Educational Objectives
At the conclusion of this program, participants should be able to:
- Explain the role of ASCT to treat patients with myeloma
- Explain the role of ASCT to treat patients with lymphoma
- Discuss side effects management and other quality of life issues for ASCT patients
- Describe key ASCT research topics
- Explain the importance of patient-provider communications
Speakers
Jonathan W. Friedberg, MD, MMSc
Professor of Medicine and Oncology
Chief, Hematology/Oncology Division
James P. Wilmot Cancer Center
University of Rochester
Rochester, New York
Edward A. Stadtmauer, MD
Professor of Medicine
Leader, Hematologic Malignancies Research Program
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Sponsors and Supporters
This program is sponsored by The Leukemia & Lymphoma Society and supported by a grant from Sanofi-Aventis.
